Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 34 entries
Sorted by: Best Match Show Resources per page
Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults.

CPT: pharmacometrics & systems pharmacology

Sampson MR, Dumitrescu TP, Brouwer KL, Schmith VD.
PMID: 24599342
CPT Pharmacometrics Syst Pharmacol. 2014 Mar 05;3:e103. doi: 10.1038/psp.2013.80.

Azithromycin's extensive distribution to proinflammatory cells, including peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells (PMNs), may be important to its antimicrobial and anti-inflammatory properties. The need to simultaneously predict azithromycin concentrations in whole blood ("blood"), PBMCs, and PMNs...

Cite
Sampson MR, Dumitrescu TP, Brouwer KL, et al. Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults. CPT Pharmacometrics Syst Pharmacol. 2014;3:e103doi: 10.1038/psp.2013.80.
Sampson, M. R., Dumitrescu, T. P., Brouwer, K. L., & Schmith, V. D. (2014). Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults. CPT: pharmacometrics & systems pharmacology, 3e103. https://doi.org/10.1038/psp.2013.80
Sampson, M R, et al. "Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults." CPT: pharmacometrics & systems pharmacology vol. 3 (2014): e103. doi: https://doi.org/10.1038/psp.2013.80
Sampson MR, Dumitrescu TP, Brouwer KL, Schmith VD. Population pharmacokinetics of azithromycin in whole blood, peripheral blood mononuclear cells, and polymorphonuclear cells in healthy adults. CPT Pharmacometrics Syst Pharmacol. 2014 Mar 05;3:e103. doi: 10.1038/psp.2013.80. PMID: 24599342; PMCID: PMC4039392.
Copy Download .nbib Format: NLM
Medical management of patients with continuous-flow left ventricular assist devices.

Current treatment options in cardiovascular medicine

Devore AD, Mentz RJ, Patel CB.
PMID: 24398802
Curr Treat Options Cardiovasc Med. 2014 Feb;16(2):283. doi: 10.1007/s11936-013-0283-0.

OPINION STATEMENT: The prevalence of patients living with advanced heart failure continues to rise. For a subset of these patients, continuous-flow left ventricular assist devices (LVADs) are a life-saving therapy. Given the efficacy and durability of contemporary LVAD devices,...

Cite
Devore AD, Mentz RJ, Patel CB. Medical management of patients with continuous-flow left ventricular assist devices. Curr Treat Options Cardiovasc Med. 2014;16(2):283doi: 10.1007/s11936-013-0283-0.
Devore, A. D., Mentz, R. J., & Patel, C. B. (2014). Medical management of patients with continuous-flow left ventricular assist devices. Current treatment options in cardiovascular medicine, 16(2), 283. https://doi.org/10.1007/s11936-013-0283-0
Devore, Adam D, et al. "Medical management of patients with continuous-flow left ventricular assist devices." Current treatment options in cardiovascular medicine vol. 16,2 (2014): 283. doi: https://doi.org/10.1007/s11936-013-0283-0
Devore AD, Mentz RJ, Patel CB. Medical management of patients with continuous-flow left ventricular assist devices. Curr Treat Options Cardiovasc Med. 2014 Feb;16(2):283. doi: 10.1007/s11936-013-0283-0. PMID: 24398802; PMCID: PMC4158403.
Copy Download .nbib Format: NLM
A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching.

Journal of chromatography & separation techniques

Wujian J, Kuan-Wei P, Sihyung Y, Huijing S, Mario S, Zhuo WM.
PMID: 26146590
J Chromatogr Sep Tech. 2015 May;6(3):268. doi: 10.4172/2157-7064.1000268.

Lovastatin is an anti-cholesterol lactone drug indicated for the treatment of hyperlipidemia and to reduce the risk of coronary heart disease. It is converted to the β-hydroxy acid form (lovastatin acid)

Cite
Wujian J, Kuan-Wei P, Sihyung Y, et al. A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching. J Chromatogr Sep Tech. 2015;6(3):268doi: 10.4172/2157-7064.1000268.
Wujian, J., Kuan-Wei, P., Sihyung, Y., Huijing, S., Mario, S., & Zhuo, W. M. (2015). A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching. Journal of chromatography & separation techniques, 6(3), 268. https://doi.org/10.4172/2157-7064.1000268
Wujian, Ju, et al. "A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching." Journal of chromatography & separation techniques vol. 6,3 (2015): 268. doi: https://doi.org/10.4172/2157-7064.1000268
Wujian J, Kuan-Wei P, Sihyung Y, Huijing S, Mario S, Zhuo WM. A Simple Protein Precipitation-based Simultaneous Quantification of Lovastatin and Its Active Metabolite Lovastatin Acid in Human Plasma by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry using Polarity Switching. J Chromatogr Sep Tech. 2015 May;6(3):268. doi: 10.4172/2157-7064.1000268. PMID: 26146590; PMCID: PMC4486316.
Copy Download .nbib Format: NLM
Population Pharmacokinetics of Doxycycline in Children.

Antimicrobial agents and chemotherapy

Thompson EJ, Wu H, Melloni C, Balevic S, Sullivan JE, Laughon M, Clark KM, Kalra R, Mendley S, Payne EH, Erinjeri J, Gelber CE, Harper B, Cohen-Wolkowiez M, Hornik CP.
PMID: 31548185
Antimicrob Agents Chemother. 2019 Sep 23; doi: 10.1128/AAC.01508-19. Epub 2019 Sep 23.

Doxycycline is a tetracycline-class antimicrobial labeled by the United States (U.S.) Food and Drug Administration for children >8 years of age for many common childhood infections. Doxycycline is not labeled for children ≤8 years of age, due to the...

Cite
Thompson EJ, Wu H, Melloni C, et al. Population Pharmacokinetics of Doxycycline in Children. Antimicrob Agents Chemother. 2019;doi: 10.1128/AAC.01508-19.
Thompson, E. J., Wu, H., Melloni, C., Balevic, S., Sullivan, J. E., Laughon, M., Clark, K. M., Kalra, R., Mendley, S., Payne, E. H., Erinjeri, J., Gelber, C. E., Harper, B., Cohen-Wolkowiez, M., Hornik, C. P. (2019). Population Pharmacokinetics of Doxycycline in Children. Antimicrobial agents and chemotherapy, . https://doi.org/10.1128/AAC.01508-19
Thompson, Elizabeth J, et al. "Population Pharmacokinetics of Doxycycline in Children." Antimicrobial agents and chemotherapy vol. (2019). doi: https://doi.org/10.1128/AAC.01508-19
Thompson EJ, Wu H, Melloni C, Balevic S, Sullivan JE, Laughon M, Clark KM, Kalra R, Mendley S, Payne EH, Erinjeri J, Gelber CE, Harper B, Cohen-Wolkowiez M, Hornik CP. Population Pharmacokinetics of Doxycycline in Children. Antimicrob Agents Chemother. 2019 Sep 23; doi: 10.1128/AAC.01508-19. Epub 2019 Sep 23. PMID: 31548185; PMCID: PMC6879254.
Copy Download .nbib Format: NLM
Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.

The Journal of rheumatology

Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, Schanberg LE, Eudy AM, Swamy GK, Hughes BL, Cohen-Wolkowiez M.
PMID: 32393664
J Rheumatol. 2020 May 11; doi: 10.3899/jrheum.200493. Epub 2020 May 11.

OBJECTIVE: To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19).METHODS: We evaluated total HCQ concentrations in serum and...

Cite
Balevic SJ, Hornik CP, Green TP, et al. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. J Rheumatol. 2020;doi: 10.3899/jrheum.200493.
Balevic, S. J., Hornik, C. P., Green, T. P., Clowse, M. E. B., Gonzalez, D., Maharaj, A. R., Schanberg, L. E., Eudy, A. M., Swamy, G. K., Hughes, B. L., & Cohen-Wolkowiez, M. (2020). Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. The Journal of rheumatology, . https://doi.org/10.3899/jrheum.200493
Balevic, Stephen J, et al. "Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials." The Journal of rheumatology vol. (2020). doi: https://doi.org/10.3899/jrheum.200493
Balevic SJ, Hornik CP, Green TP, Clowse MEB, Gonzalez D, Maharaj AR, Schanberg LE, Eudy AM, Swamy GK, Hughes BL, Cohen-Wolkowiez M. Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials. J Rheumatol. 2020 May 11; doi: 10.3899/jrheum.200493. Epub 2020 May 11. PMID: 32393664; PMCID: PMC7655510.
Copy Download .nbib Format: NLM
All You Need to Know About .

JCO oncology practice

Karas S, Innocenti F.
PMID: 34860573
JCO Oncol Pract. 2021 Dec 03;OP2100624. doi: 10.1200/OP.21.00624. Epub 2021 Dec 03.

Irinotecan is an anticancer agent widely used for the treatment of solid tumors, including colorectal and pancreatic cancers. Severe neutropenia and diarrhea are common dose-limiting toxicities of irinotecan-based therapy, and

Cite
Karas S, Innocenti F. All You Need to Know About . JCO Oncol Pract. 2021;OP2100624doi: 10.1200/OP.21.00624.
Karas, S., & Innocenti, F. (2021). All You Need to Know About . JCO oncology practice, OP2100624. https://doi.org/10.1200/OP.21.00624
Karas, Spinel, and Innocenti, Federico. "All You Need to Know About ." JCO oncology practice vol. (2021): OP2100624. doi: https://doi.org/10.1200/OP.21.00624
Karas S, Innocenti F. All You Need to Know About . JCO Oncol Pract. 2021 Dec 03;OP2100624. doi: 10.1200/OP.21.00624. Epub 2021 Dec 03. PMID: 34860573.
Copy Download .nbib Format: NLM
Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains.

Genes, brain, and behavior

Zhu J, Beechinor RJ, Thompson T, Schorzman AN, Zamboni W, Crona DJ, Weiner DL, Tarantino LM.
PMID: 32383297
Genes Brain Behav. 2021 Feb;20(2):e12666. doi: 10.1111/gbb.12666. Epub 2020 May 29.

Cocaine (COC) is a psychostimulant with a high potential for abuse and addiction. Risk for COC use disorder is driven, in part, by genetic factors. Animal models of addiction-relevant behaviors have proven useful for studying both genetic and nongenetic...

Cite
Zhu J, Beechinor RJ, Thompson T, et al. Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains. Genes Brain Behav. 2020;20(2):e12666doi: 10.1111/gbb.12666.
Zhu, J., Beechinor, R. J., Thompson, T., Schorzman, A. N., Zamboni, W., Crona, D. J., Weiner, D. L., & Tarantino, L. M. (2021). Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains. Genes, brain, and behavior, 20(2), e12666. https://doi.org/10.1111/gbb.12666
Zhu, Jing, et al. "Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains." Genes, brain, and behavior vol. 20,2 (2021): e12666. doi: https://doi.org/10.1111/gbb.12666
Zhu J, Beechinor RJ, Thompson T, Schorzman AN, Zamboni W, Crona DJ, Weiner DL, Tarantino LM. Pharmacokinetic and pharmacodynamic analyses of cocaine and its metabolites in behaviorally divergent inbred mouse strains. Genes Brain Behav. 2021 Feb;20(2):e12666. doi: 10.1111/gbb.12666. Epub 2020 May 29. PMID: 32383297; PMCID: PMC7941260.
Copy Download .nbib Format: NLM
Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains.

Pediatric blood & cancer

Ellis GK, Chapman H, Manda A, Salima A, Itimu S, Banda G, Seguin R, Manda G, Butia M, Huibers M, Ozuah N, Tilly A, Stover AM, Basch E, Gopal S, Reeve BB, Westmoreland KD.
PMID: 34339099
Pediatr Blood Cancer. 2021 Oct;68(10):e29257. doi: 10.1002/pbc.29257. Epub 2021 Aug 02.

BACKGROUND: Patient-reportedoutcomes (PROs) that assess health-related quality of life (HRQoL) are increasingly important components of cancer care and research that are infrequently used in sub-Saharan Africa (SSA).METHODS: We administered the Chichewa Pediatric Patient-Reported Outcome Measurement Information System Pediatric (PROMIS)-25...

Cite
Ellis GK, Chapman H, Manda A, et al. Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains. Pediatr Blood Cancer. 2021;68(10):e29257doi: 10.1002/pbc.29257.
Ellis, G. K., Chapman, H., Manda, A., Salima, A., Itimu, S., Banda, G., Seguin, R., Manda, G., Butia, M., Huibers, M., Ozuah, N., Tilly, A., Stover, A. M., Basch, E., Gopal, S., Reeve, B. B., & Westmoreland, K. D. (2021). Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains. Pediatric blood & cancer, 68(10), e29257. https://doi.org/10.1002/pbc.29257
Ellis, Grace K, et al. "Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains." Pediatric blood & cancer vol. 68,10 (2021): e29257. doi: https://doi.org/10.1002/pbc.29257
Ellis GK, Chapman H, Manda A, Salima A, Itimu S, Banda G, Seguin R, Manda G, Butia M, Huibers M, Ozuah N, Tilly A, Stover AM, Basch E, Gopal S, Reeve BB, Westmoreland KD. Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains. Pediatr Blood Cancer. 2021 Oct;68(10):e29257. doi: 10.1002/pbc.29257. Epub 2021 Aug 02. PMID: 34339099; PMCID: PMC8497011.
Copy Download .nbib Format: NLM
Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments.

Therapeutic advances in infectious disease

Bϋdingen FV, Gonzalez D, Tucker AN, Derendorf H.
PMID: 24949199
Ther Adv Infect Dis. 2014 Feb 01;2(1):17-42. doi: 10.1177/2049936113519089.

The liver is a complex organ with great ability to influence drug pharmacokinetics. Due to its wide array of function, its impairment has the potential to affect bioavailability, enterohepatic circulation, drug distribution, metabolism, clearance, and biliary elimination. These alterations...

Cite
Bϋdingen FV, Gonzalez D, Tucker AN, et al. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis. 2014;2(1):17-42doi: 10.1177/2049936113519089.
Bϋdingen, F. V., Gonzalez, D., Tucker, A. N., & Derendorf, H. (2014). Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Therapeutic advances in infectious disease, 2(1), 17-42. https://doi.org/10.1177/2049936113519089
Bϋdingen, Fiona V, et al. "Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments." Therapeutic advances in infectious disease vol. 2,1 (2014): 17-42. doi: https://doi.org/10.1177/2049936113519089
Bϋdingen FV, Gonzalez D, Tucker AN, Derendorf H. Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments. Ther Adv Infect Dis. 2014 Feb 01;2(1):17-42. doi: 10.1177/2049936113519089. PMID: 24949199; PMCID: PMC4059611.
Copy Download .nbib Format: NLM
HIV PrEP Trials: The Road to Success.

Clinical investigation

Nicol MR, Adams JL, Kashuba AD.
PMID: 24409341
Clin Investig (Lond). 2013 Mar;3(3). doi: 10.4155/cli.12.155.

The global HIV epidemic cannot be controlled by current treatment or prevention strategies. Pre-exposure prophylaxis (PrEP) using antiretrovirals is a promising approach to curbing the spread of HIV transmission. Recently, four clinical trials demonstrated favorable results when antiretroviral PrEP...

Cite
Nicol MR, Adams JL, Kashuba AD. HIV PrEP Trials: The Road to Success. Clin Investig (Lond). 2013;3(3)doi: 10.4155/cli.12.155.
Nicol, M. R., Adams, J. L., & Kashuba, A. D. (2013). HIV PrEP Trials: The Road to Success. Clinical investigation, 3(3), . https://doi.org/10.4155/cli.12.155
Nicol, Melanie R, et al. "HIV PrEP Trials: The Road to Success." Clinical investigation vol. 3,3 (2013). doi: https://doi.org/10.4155/cli.12.155
Nicol MR, Adams JL, Kashuba AD. HIV PrEP Trials: The Road to Success. Clin Investig (Lond). 2013 Mar;3(3). doi: 10.4155/cli.12.155. PMID: 24409341; PMCID: PMC3882078.
Copy Download .nbib Format: NLM
Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation.

Journal of clinical pharmacology

Commander SJ, Wu H, Boakye-Agyeman F, Melloni C, Hornik CD, Zimmerman K, Al-Uzri A, Mendley SR, Harper B, Cohen-Wolkowiez M, Hornik CP.
PMID: 33029806
J Clin Pharmacol. 2021 Mar;61(3):368-377. doi: 10.1002/jcph.1739. Epub 2020 Oct 07.

Hydrochlorothiazide (HCTZ) is a thiazide diuretic used in adults and children for the treatment of hypertension and edema. The pharmacokinetic (PK) properties of HCTZ in children are not well characterized, particularly among children with obesity who frequently suffer from...

Cite
Commander SJ, Wu H, Boakye-Agyeman F, et al. Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation. J Clin Pharmacol. 2020;61(3):368-377doi: 10.1002/jcph.1739.
Commander, S. J., Wu, H., Boakye-Agyeman, F., Melloni, C., Hornik, C. D., Zimmerman, K., Al-Uzri, A., Mendley, S. R., Harper, B., Cohen-Wolkowiez, M., Hornik, C. P. (2021). Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation. Journal of clinical pharmacology, 61(3), 368-377. https://doi.org/10.1002/jcph.1739
Commander, Sarah Jane, et al. "Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation." Journal of clinical pharmacology vol. 61,3 (2021): 368-377. doi: https://doi.org/10.1002/jcph.1739
Commander SJ, Wu H, Boakye-Agyeman F, Melloni C, Hornik CD, Zimmerman K, Al-Uzri A, Mendley SR, Harper B, Cohen-Wolkowiez M, Hornik CP. Pharmacokinetics of Hydrochlorothiazide in Children: A Potential Surrogate for Renal Secretion Maturation. J Clin Pharmacol. 2021 Mar;61(3):368-377. doi: 10.1002/jcph.1739. Epub 2020 Oct 07. PMID: 33029806; PMCID: PMC8232568.
Copy Download .nbib Format: NLM
Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables.

Frontiers in pharmacology

Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D.
PMID: 32390828
Front Pharmacol. 2020 Apr 22;11:420. doi: 10.3389/fphar.2020.00420. eCollection 2020.

The administered dose of a drug modulates whether patients will experience optimal effectiveness, toxicity including death, or no effect at all. Dosing is particularly important for diseases and/or drugs where the drug can decrease severe morbidity or prolong life....

Cite
Tyson RJ, Park CC, Powell JR, et al. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front Pharmacol. 2020;11:420doi: 10.3389/fphar.2020.00420.
Tyson, R. J., Park, C. C., Powell, J. R., Patterson, J. H., Weiner, D., Watkins, P. B., & Gonzalez, D. (2020). Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Frontiers in pharmacology, 11420. https://doi.org/10.3389/fphar.2020.00420
Tyson, Rachel J, et al. "Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables." Frontiers in pharmacology vol. 11 (2020): 420. doi: https://doi.org/10.3389/fphar.2020.00420
Tyson RJ, Park CC, Powell JR, Patterson JH, Weiner D, Watkins PB, Gonzalez D. Precision Dosing Priority Criteria: Drug, Disease, and Patient Population Variables. Front Pharmacol. 2020 Apr 22;11:420. doi: 10.3389/fphar.2020.00420. eCollection 2020. PMID: 32390828; PMCID: PMC7188913.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 34 entries